2018 American Society of Clinical Oncology Annual Meeting*

ASCO 2018 Program Image
Download All
June 1-5, 2018; Chicago, Illinois
This program provides coverage of the 2018 ASCO annual meeting with summary slidesets and expert analyses of key results in gastrointestinal cancers, gynecologic cancers, skin cancer, cancer immunotherapy, genitourinary cancers, hematologic malignancies, breast cancer, and lung cancer.

Lung Cancer

Capsule Summary Slidesets

LOXO-292 showed robust and durable activity in previously treated patients with RET-altered tumors, including NSCLC, regardless of prior therapy.

Released: June 5, 2018

Pembrolizumab addition to platinum-based chemotherapy significantly improved PFS and OS as first-line therapy for metastatic squamous NSCLC, with benefit demonstrated regardless of PD-L1 expression level.

Released: June 13, 2018

In this phase II trial, consolidation pembrolizumab improved time to metastatic disease or death and PFS compared with historical outcomes.

Released: June 5, 2018

In preliminary results, first-line combination chemoimmunotherapy with durvalumab achieved an ORR of 58% and 6-month PFS of 65% in advanced MPM.

Released: June 6, 2018

Pembrolizumab showed promising antitumor activity in patients with SCLC, particularly those with PD-L1–positive tumors.

Released: June 13, 2018

For patients with < 1% PD-L1 tumor expression, PFS benefit with first-line nivolumab combinations was limited to those who also had high tumor mutational burden.

Released: June 7, 2018

Addition of atezolizumab to carboplatin/paclitaxel + bevacizumab significantly prolonged PFS and OS when given as first-line therapy in advanced nonsquamous NSCLC.

Released: June 12, 2018

In patients with advanced EGFR mutation–positive NSCLC, first-line dacomitinib significantly improved OS vs gefitinib by 7.3 months with a 24% reduced risk of death.

Released: June 12, 2018

In this planned interim analysis, first-line pembrolizumab significantly improved OS vs CT in patients with NSCLC and PD-L1 TPS ≥ 1% with a 19% reduced risk of death.

Released: June 13, 2018

Sequencing of plasma cfDNA noninvasively identified patients with lung cancer regardless of stage, method of diagnosis, histology, or smoking status.

Released: June 7, 2018

Addition of atezolizumab to carboplatin/nab-paclitaxel extended PFS compared with chemotherapy alone in patients with previously untreated metastatic squamous NSCLC.

Released: June 11, 2018
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings